Reachable workspace in facioscapulohumeral muscular dystrophy (FSHD) by kinect

Muscle and Nerve

Volumn 51, Issue 2, 2015, Pages 168-175

  Han, Jay J ^a   Kurillo, Gregorij ^a,b   Abresch, Richard T ^a   de Bie, Evan ^a   Nicorici, Alina ^a   Bajcsy, Ruzena ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FSHD; Function; Kinect reachable workspace; Upper extremity

Indexed keywords

ADULT; AGED; CASE CONTROL STUDY; COHORT ANALYSIS; DEVICES; FEMALE; HEMISPHERIC DOMINANCE; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; MIDDLE AGED; MOVEMENT (PHYSIOLOGY); MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; REMOTE SENSING; SKELETAL MUSCLE; UPPER LIMB;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; MIDDLE AGED; MOVEMENT; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; RANGE OF MOTION, ARTICULAR; REMOTE SENSING TECHNOLOGY; UPPER EXTREMITY;

EID: 84920929253     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24287     Document Type: Article

References (28)

1. Tawil R. Facioscapulohumeral muscular dystrophy. Neurotherapeutics 2008;5:601-606.
2. Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord 2001;11:525-529.
3. Mostacciuolo ML, Pastorello E, Vazza G, Miorin M, Angelini C, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin Genet 2009;75:550-555.
4. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 1993;2:2037-2042.
5. Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, Dauwerse HG, et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 1992;2:26-30.
6. Van der Maarel SM, Tawil R, Tapscott SJ. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol Med 2011;17:252-258.
7. Tawil R, Van Der Maarel SM. Facioscapulohumeral muscular dystrophy. Muscle Nerve 2006;34:1-15.
8. Kilmer DD, Abresch RT, McCrory MA, Carter GT, Fowler WM Jr, Johnson ER, et al. Profiles of neuromuscular diseases. Facioscapulohumeral muscular dystrophy. Am J Phys Med Rehabil 1995;74(Suppl):S131-S139.
9. Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol 2011;24:423-428.
10. Wallace LM, Liu J, Domire JS, Garwick-Coppens SE, Guckes SM, Mendell JR, et al. RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy. Mol Ther 2012;20:1417-1423.
11. Leung DG, Wagner KR. Therapeutic advances in muscular dystrophy. Ann Neurol 2013;74:404-411.
12. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013;48:357-368.
13. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 2013;74:637-647.
14. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362:1396-1406.
15. Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond) 2011;1:1217-1235.
16. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, et al. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops. Neuromuscul Disord 2008;18:894-903.
17. Bartels B, Pangalila RF, Bergen MP, Cobben NA, Stam HJ, Roebroeck ME. Upper limb function in adults with Duchenne muscular dystrophy. J Rehabil Med 2011;43:770-775.
18. Muntoni F. The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009. Neuromuscul Disord 2010;20:355-362.
19. Kurillo G, Han JJ, Abresch RT, Nicorici A, Yan P, Bajcsy R. Development and application of stereo camera-based upper extremity workspace evaluation in patients with neuromuscular diseases. PLoS One 2012;7:e45341.
20. Han JJ, Kurillo G, Abresch RT, Nicorici A, Bajcsy R. Validity, reliability, and sensitivity of a 3D vision sensor-based upper extremity reachable workspace evaluation in neuromuscular diseases. PLoS Curr 2013;5:pii.
21. Kurillo G, Han JJ, Obdrzalek S, Yan P, Abresch RT, Nicorici A, et al. Upper extremity reachable workspace evaluation with Kinect. Stud Health Technol Inform 2013;184:247-253.
22. Kurillo G, Chen A, Bajcsy R, Han JJ. Evaluation of upper extremity reachable workspace using Kinect camera. Technol Health Care 2013;21:641-656.
23. Lamperti C, Fabbri G, Vercelli L, D'Amico R, Frusciante R, Bonifazi E, et al. A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: the FSHD clinical score. Muscle Nerve 2010;42:213-217.
24. Sharpless JW. The nine hole peg test of finger hand co-ordination for the hemiplegic patient. In: Sharpless JW, editor. Mossman's a problem oriented approach to stroke rehabilitation. Springfield, IL: Charles CT Thomas; 1982. p 420-423.
25. Jebsen RH, Taylor N, Trieschmann RB, Trotter MJ, Howard LA. An objective and standardized test of hand function. Arch Phys Med Rehabil 1969;50:311-319.
26. Brooke M, Griggs R, Mendell J, Fenichel G, Shumate J, Pellegrino R. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981;4:186-197.
27. Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med 1996;29:602-608. Erratum in: Am J Ind Med 1996;30:372.
28. Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC. Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology 1994;44(3 Pt 1):442-446.